// App-Quantinova.ai

FR-OR58 : Effects of Dapagliflozin on Kidney Function, Cardiovascular Events, and All-Cause Mortality According to Cause of Kidney Disease in the DAPA-CKD Trial

Researchers

Presenter

  • Wheeler DavidC

Principal Investigators

  • Stefansson BergurV

  • Correa-Rotter Ricardo

  • Chertow GlennMatthew

  • Greene Tom

  • Hou Fan Fan

  • Jongs Niels

  • McMurray John

  • Rossing Peter

  • Sjostrom David

  • Toto RobertD

  • Langkilde Anna Maria

  • L Heerspink HiddoJan

Medical Centers

  • The George Inst. for Global Hlth., Sydney, Australia

  • AstraZeneca, Gothenburg, Sweden

  • National Medical Science and Nutrition Institute Salvador Zubirán Mexico City Mexico

  • Stanford University Medical Center, Stanford, California, United States

  • University of Utah Health Sciences Center, Salt Lake City, Utah, United States

  • Southern Medical University Nanfang Hospital, Guangzhou, China

  • University of Groningen, Groningen, Netherlands

  • University of Glasgow, Institute of Cardiovascular and Medical Sciences, Glasgow, United Kingdom

  • Steno Diabetes Center Copenhagen,

  • UT Southwestern Medical Center, Dallas, Texas, United States

Locations

  • Australia

  • Sweden

  • Mexico

  • United States

  • China

  • Netherlands

  • United Kingdom

  • Denmark

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

Disease

  • Microvascular complications of diabetes 1

  • Diabetic nephropathy

  • Renal disease

  • Congestive heart failure

Biomarkers

  • N/A

Drug/Treatment

  • Dapagliflozin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved